1. Signaling Pathways
  2. GPCR/G Protein
  3. Angiotensin Receptor
  4. AT1 Receptor Isoform
  5. AT1 Receptor Antagonist

AT1 Receptor Antagonist

AT1 Receptor Antagonists (21):

Cat. No. Product Name Effect Purity
  • HY-17512
    Losartan
    Antagonist 99.67%
    Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
  • HY-13955
    Telmisartan
    Antagonist 99.81%
    Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
  • HY-18204
    Valsartan
    Antagonist 99.87%
    Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.
  • HY-19202
    rac-Olodanrigan
    Antagonist
    rac-Olodanrigan (rac-EMA401; EMA400) is a racemic mixture of the S-enantiomer (EMA401; HY-13106) and R-enantiomer (EMA402). rac-Olodanrigan is a potent and selective AT2 receptor antagonist with IC50s of 75.2 nM and 2918 nM for AT2R and AT1R, respectively. rac-Olodanrigan evokes dose-dependent relief of mechanical allodynia in the ipsilateral hind paws of rats with a chronic constriction injury (CCI) of the sciatic nerve.
  • HY-12403
    Talfirastide
    Antagonist 99.91%
    Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
  • HY-P0216
    A 779
    Antagonist 98.59%
    A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor), which is an Ang1-7 receptor distinct from the classical AngII.
  • HY-17512A
    Losartan potassium
    Antagonist 99.91%
    Losartan potassium (DuP-753 potassium) is an angiotensin II receptor type 1 (AT1) antagonist, competing with the binding of angiotensin II to AT1 with an IC50 of 20 nM.
  • HY-17004
    Olmesartan
    Antagonist 99.91%
    Olmesartan (RNH-6270) is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure.
  • HY-14736
    Azilsartan medoxomil
    Antagonist 99.88%
    Azilsartan medoxomil (TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.
  • HY-14914
    Azilsartan
    Antagonist 99.51%
    Azilsartan (TAK-536) is an orally active, potent, selective and specific angiotensin II type 1 receptor (AT1) antagonist. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. Azilsartan can be used for hypertension and stroke research.
  • HY-12403A
    Talfirastide acetate
    Antagonist 99.87%
    Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium.
  • HY-A0250
    Tasosartan
    Antagonist 99.07%
    Tasosartan is a long-acting angiotensin II (AngII) receptor antagonist.
  • HY-B0780
    Fimasartan
    Antagonist 98.55%
    Fimasartan(BR-A-657) is a non-peptide angiotensin II receptor antagonist used for the treatment of hypertension and heart failure.
  • HY-19732
    BIBS 39
    Antagonist 99.70%
    BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist.
  • HY-18204S
    Valsartan-d9
    Antagonist 99.33%
    Valsartan-d9 is deuterium labeled valsartan. Valsartan is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research[1].
  • HY-131278
    Olmesartan methyl ester
    Antagonist
    Olmesartan methyl ester is an intermediate in the synthesis of Olmesartan medoxomil. Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor antagonist with IC50 of 66.2 μM.
  • HY-17004S1
    Olmesartan-d6
    Antagonist 98.62%
    Olmesartan-d6 (RNH-6270-d6) is the deuterium labeled Olmesartan. Olmesartan (RNH-6270) is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure[1][2].
  • HY-17458
    Azilsartan medoxomil monopotassium
    Antagonist
    Azilsartan medoxomil monopotassium is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.
  • HY-100292
    SL910102
    Antagonist
    SL910102 is a nonpeptide angiotensin AT1 receptor antagonist.
  • HY-103247
    EMD 66684
    Antagonist
    EMD 66684 is an antagonist of Angiotensin II Type 1 (AT1) receptor. EMD 66684 shows potent binding affinities for the AT1 subtype Ang II receptor with an IC50 value of 0.7 nM. EMD 66684 also serves as an antiischemic cytoprotectant -.